Boehringer Ingelheim Invests 62 Million Euros in R&D&i in Spain, 36% More

Boehringer Ingelheim Spain has increased its investment in research, development and innovation (R&D&I) to 62.7 million euros in the last year. This represents a growth of 36% compared to the previous year, when the company disbursed 46.1 million euros in this concept.

These data represent 11.5% of the net sales of the prescription pharmaceutical products segment, the Boehringer Ingelheim says in a statement.

At the moment, the company’s human health division focuses on six main therapeutic R&D areas: cardio, renal and metabolic (CRM) diseases, oncology, respiratory diseases, immunological diseases, mental health and retinal health. For its animal health division, Boehringer prevents and treats diseases in animals, offering a range of vaccines, dewormers and medications for companion animals, horses, as well as production animals.

The company has two strategic international pharmaceutical production plants in Spain for injectables and orals, on the one hand, and, on the other, the center for the manufacturing and packaging of its Respimat device for respiratory diseases.

Boehringer Ingelheim plans to allocate 93.4 million euros until 2027 for a new technological production platform

In the last seven years, the pharmaceutical company Boehringer Ingelheim has made investments worth 224.5 million euros in these production plants, from which it exports to more than eighty countries . Boehringer plans to allocate 93.4 million euros from 2024 to 2027 for a new technological production platform.

In the same national headquarters, the company has two units dedicated exclusively to R&D, as well as three international hubs : IT Hub, the Global Digital Services Hub and the Regulatory Affairs Hub.

“From Spain we have shown our relevance as a strategic site for the group at a global level, being the fourth country with the highest number of clinical trials of the corporation and the third with the most oncology trials,” declared Peter Ploeger, general director of Boehringer Ingelheim in the country.

__

(Featured image by alanajordan via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us